Compare FSBW & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSBW | LCTX |
|---|---|---|
| Founded | 1936 | 1990 |
| Country | United States | United States |
| Employees | 537 | N/A |
| Industry | Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 326.3M | 301.7M |
| IPO Year | 2011 | 1996 |
| Metric | FSBW | LCTX |
|---|---|---|
| Price | $43.99 | $1.07 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $46.00 | $6.25 |
| AVG Volume (30 Days) | 18.1K | ★ 932.4K |
| Earning Date | 04-21-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.79% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.07 | N/A |
| Revenue | $4,612,000.00 | ★ $14,556,000.00 |
| Revenue This Year | $14.94 | $109.40 |
| Revenue Next Year | $10.47 | N/A |
| P/E Ratio | $21.15 | ★ N/A |
| Revenue Growth | 44.80 | ★ 53.24 |
| 52 Week Low | $36.85 | $1.00 |
| 52 Week High | $45.85 | $2.09 |
| Indicator | FSBW | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.07 | 39.65 |
| Support Level | $40.96 | $1.00 |
| Resistance Level | $43.70 | $1.18 |
| Average True Range (ATR) | 0.95 | 0.06 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 70.87 | 36.11 |
FS Bancorp Inc is the holding company of First Security Bank, a diversified lender with a focus on the origination of commercial real estate, one-to-four-family, and home equity loans, consumer loans, including a variety of indirect home improvement (fixture secured loans), and marine loans, and commercial business loans. The company has two operating segments; The commercial and consumer banking segment provides diversified financial products and services to its commercial and consumer customers through Bank branches, automated teller machines, online banking platforms, mobile banking apps, and telephone banking; and The home lending segment originates one-to-four-family residential mortgage loans for sale in the secondary markets as well as loans held for investment.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.